

Revance Therapeutics, Inc.  
 Form 3  
 February 05, 2014

**FORM 3 UNITED STATES SECURITIES AND EXCHANGE COMMISSION**  
**Washington, D.C. 20549**

OMB APPROVAL

OMB Number: 3235-0104  
 Expires: January 31, 2005  
 Estimated average burden hours per response... 0.5

**INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES**

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934,  
 Section 17(a) of the Public Utility Holding Company Act of 1935 or Section  
 30(h) of the Investment Company Act of 1940

(Print or Type Responses)

1. Name and Address of Reporting Person * Rugg Curtis (Last) (First) (Middle)	2. Date of Event Requiring Statement (Month/Day/Year) 02/05/2014	3. Issuer Name and Ticker or Trading Symbol Revance Therapeutics, Inc. [RVNC]	4. Relationship of Reporting Person(s) to Issuer  (Check all applicable)  <input type="checkbox"/> Director <input type="checkbox"/> 10% Owner <input checked="" type="checkbox"/> Officer <input type="checkbox"/> Other (give title below) (specify below) EVP R&D and Tech Operations	5. If Amendment, Date Original Filed(Month/Day/Year)
---	--	--	---	--

C/O REVANCE  
 THERAPEUTICS, INC., 7555  
 GATEWAY BOULEVARD  
 (Street)

NEWARK, CA 94560  
 (City) (State) (Zip)

6. Individual or Joint/Group Filing(Check Applicable Line)  
 Form filed by One Reporting Person  
 Form filed by More than One Reporting Person

**Table I - Non-Derivative Securities Beneficially Owned**

1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
Common Stock	3,606 <sup>(1)</sup>	D	

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly. SEC 1473 (7-02)

**Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.**

**Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)**

1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)	3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)	4. Conversion or Exercise Price of Derivative	5. Ownership Form of Derivative Security:	6. Nature of Indirect Beneficial Ownership (Instr. 5)
---	---	--	---	---	--

Edgar Filing: Revance Therapeutics, Inc. - Form 3

	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	Security	Direct (D) or Indirect (I) (Instr. 5)	
Stock Option (Right to Buy)	Â (2)	05/15/2016	Common Stock	4,333 (1)	\$ 6.6 (3)	D	Â
Stock Option (Right to Buy)	Â (4)	12/11/2016	Common Stock	9,333 (1)	\$ 6.6 (3)	D	Â
Stock Option (Right to Buy)	Â (5)	04/29/2018	Common Stock	1,666 (1)	\$ 2.55 (3)	D	Â
Stock Option (Right to Buy)	Â (6)	07/20/2020	Common Stock	5,666 (1)	\$ 2.55 (3)	D	Â
Stock Option (Right to Buy)	Â (7)	05/26/2023	Common Stock	60,000 (1)	\$ 8.7 (3)	D	Â
Stock Option (Right to Buy)	Â (8)	12/16/2023	Common Stock	19,999 (1)	\$ 9.15 (3)	D	Â

## Reporting Owners

Reporting Owner Name / Address	Relationships			
	Director	10% Owner	Officer	Other
Ruegg Curtis C/O REVANCE THERAPEUTICS, INC. 7555 GATEWAY BOULEVARD NEWARK, CA 94560	Â	Â	Â EVP R&D and Tech Operations	Â

## Signatures

/s/ Gordon Ho,  
Attorney-in-fact

02/05/2014

\*\*Signature of Reporting Person

Date

## Explanation of Responses:

\* If the form is filed by more than one reporting person, see Instruction 5(b)(v).

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

(1) Reflect a 1-for-15 reverse split of the Issuer's issued and outstanding securities effective February 3, 2014.

(2) The Option is fully vested as of May 16, 2010.

(3) Price reflects 1-for-15 reverse stock split

(4) The Option is fully vested as of September 29, 2010.

(5) The Option is fully vested as of January 1, 2012.

(6) The Option is fully vested as of January 1, 2014.

(7) The Option shares shall vest as follows: 1/48th of the total number of shares subject to the Option shall vest in 48 equal monthly installments over 4 years following May 27, 2013, subject to Reporting Person's Continuous Service (as defined in the Issuer's 2012 Equity Incentive Plan) as of such date.

(8) The Option shares shall vest as follows: 1/48th of the total number of shares subject to the Option shall vest in 48 equal monthly installments over 4 years following December 17, 2013, subject to Reporting Person's Continuous Service (as defined in the Issuer's 2012

## Edgar Filing: Revance Therapeutics, Inc. - Form 3

Equity Incentive Plan) as of such date.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *See* Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.